# Corline Biomedical > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/corlinebiomedical). ## Overview Corline Biomedical is a Swedish medical technology company focused on CHS™, a heparin-based surface technology used to make blood-contacting medical devices more biocompatible. The company develops and supplies products, reagents, and licensing-based solutions for device manufacturers, with a commercial focus in cardiovascular and catheter-based applications. ## Products & services • CHS™ surface technology for blood-contacting devices • Products and reagents for device coating workflows • Licensing and supply agreements for CHS™ use • Application support for medical device integration - **CHS™ surface technology** (55%) — Heparin-based surface technology used to improve blood compatibility in medical devices. - **Products and reagents** (35%) — Commercially supplied products and reagents used in coating and device workflows. - **Licensing and supply agreements** (10%) — Longer-term agreements that grant customers rights to use Corline's technology and supply chain. - CHS™ surface technology for blood-contacting devices - Products and reagents for device coating workflows - Licensing and supply agreements for CHS™ use - Application support for medical device integration ## Customers Corline sells primarily to medical device companies that need blood-compatible surfaces for catheters and other blood-contacting products. The most visible end market in the reports is pulsed field ablation (PFA) for cardiac arrhythmia treatment, where CHS™ is used in catheter-based systems. The company also addresses broader medtech customers that may adopt CHS™ as a standard antithrombotic solution. - **PFA catheter manufacturers** (primary) — Buy CHS™-enabled solutions for pulsed field ablation catheter systems because blood compatibility is critical in cardiac procedures. - **Medical device OEMs** (primary) — Purchase products, reagents, and technology access for blood-contacting devices that need antithrombotic surface treatment. - **Existing commercial accounts** (secondary) — Buy recurring products and reagents used in ongoing device production and development workflows. - **Prospective medtech adopters** (emerging) — Evaluate CHS™ as a standard surface solution for broader device categories beyond the current core accounts. - Medical device OEMs integrating CHS™ into catheter systems - Cardiac ablation customers using blood-contacting components - PFA platform developers seeking safer device surfaces - Existing commercial customers buying products and reagents - Potential new medtech customers evaluating CHS™ adoption ## Geography Corline is headquartered in Sweden and appears to operate as a small, internationally oriented medtech supplier. The reports highlight commercial focus on the U.S. market through CHS™ supply relationships, while the customer base is tied to global medical device development and manufacturing. Geography matters because regulatory approval, customer qualification, and device commercialization are all tied to specific markets and OEM programs. - Sweden is the corporate base and reporting center - U.S. market is strategically important for CHS™ commercialization - Business is tied to global medtech OEM supply chains - Customer programs can span multiple geographies and regulatory regimes ## Strategy Corline's strategy is to expand commercial deliveries of products and reagents while broadening CHS™ adoption across more medical device customers. A central priority is the Kardium Globe® PFA program, which can validate the technology in a fast-growing cardiac ablation market and support wider customer adoption. The company also aims to convert its technology into longer-term licensing and supply relationships that can scale beyond a single device platform. - **Expand commercial product and reagent deliveries** (short-term) — Recurring commercial sales improve visibility and support broader adoption of the technology. - **Scale the Kardium Globe® PFA program** (medium-term) — A successful platform relationship can anchor volume and validate CHS™ in a fast-growing market. - **Broaden CHS™ into additional medtech accounts** (medium-term) — A wider customer base reduces dependence on any single program and expands addressable demand. - Grow product and reagent sales as the commercial base expands - Deepen the Kardium Globe® relationship in PFA applications - Use CHS™ as a platform for broader medtech customer adoption - Convert technology validation into repeatable supply agreements - Target higher-value recurring revenue from commercial deliveries ## Risks Corline depends on successful customer qualification, regulatory approvals, and adoption of its CHS™ technology in a specialized medtech market. The business is exposed to concentration risk in a small number of programs, as well as execution risk if expected customer uptake or device commercialization is delayed. Like other early commercial medtech suppliers, it also faces technical, regulatory, and reimbursement-related uncertainty in end markets such as cardiac ablation. - **Customer concentration** [high] — A limited number of commercial programs can materially affect revenue if one account slows or ends. - **Regulatory and product approval risk** [high] — Medical device adoption depends on approvals, validation, and customer qualification cycles. - **Technology adoption risk** [medium] — CHS™ must prove performance and reliability across customer programs before scaling broadly. - **Market concentration in PFA** [medium] — A meaningful part of the growth case is tied to one fast-growing but specialized end market. - Customer concentration in a small number of device programs - Regulatory and FDA-related timing risk for medtech adoption - Commercial adoption risk if CHS™ is not broadly qualified - Dependence on successful execution in PFA and catheter markets - Small-company volatility in revenue and operating scale ## Accounting Corline's reported revenue mix can shift materially between development-related activity and commercial deliveries of products and reagents, which affects comparability across quarters. Investors should also watch how the company recognizes revenue from supply and licensing arrangements, since timing can differ between delivery, acceptance, and contract milestones. As a small listed medtech company, estimates around receivables, inventory, and any capitalized development-related items can also influence reported results. - **Revenue recognition timing** — Can cause quarter-to-quarter volatility in reported revenue - **Revenue mix between products and other activities** — Affects gross margin profile and comparability - **Small-base quarterly comparability** — Makes trend analysis sensitive to one-off deliveries - Revenue mix can shift between commercial deliveries and other activity - Supply and licensing contracts may have milestone or acceptance timing - Quarterly comparability is affected by small absolute revenue base - Receivables and inventory estimates matter in a small medtech business - K3 reporting and note judgments can affect presentation and timing --- *Last updated: 2026-08-11T04:04:51.714072+00:00*